These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34681181)

  • 1. Peptide Nanoparticle-Mediated Combinatorial Delivery of Cancer-Related siRNAs for Synergistic Anti-Proliferative Activity in Triple Negative Breast Cancer Cells.
    Egorova A; Pyankov I; Maretina M; Baranov V; Kiselev A
    Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration.
    JingSong H; Hong G; Yang J; Duo Z; Li F; WeiCai C; XueYing L; YouSheng M; YiWen O; Yue P; Zou C
    Oncotarget; 2017 Jan; 8(2):2585-2593. PubMed ID: 27906681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Anti-Angiogenic Effects Using Peptide-Based Combinatorial Delivery of siRNAs Targeting VEGFA, VEGFR1, and Endoglin Genes.
    Egorova AA; Shtykalova SV; Maretina MA; Sokolov DI; Selkov SA; Baranov VS; Kiselev AV
    Pharmaceutics; 2019 Jun; 11(6):. PubMed ID: 31174285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
    Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
    Zhang C; Yuan W; Wu Y; Wan X; Gong Y
    Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
    Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
    Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
    Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
    Tilli TM; Carels N; Tuszynski JA; Pasdar M
    Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
    Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
    Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
    Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
    Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
    Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypically Screened Carbon Nanoparticles for Enhanced Combinatorial Therapy in Triple Negative Breast Cancer.
    Kampert T; Misra SK; Srivastava I; Tripathi I; Pan D
    Cell Mol Bioeng; 2017 Oct; 10(5):371-386. PubMed ID: 31719869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
    Li G; Yang M; Zuo L; Wang MX
    Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGFA Gene Silencing in CXCR4-Expressing Cells via siRNA Delivery by Means of Targeted Peptide Carrier.
    Egorova AA; Maretina MA; Kiselev AV
    Methods Mol Biol; 2019; 1974():57-68. PubMed ID: 31098995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.